Carregant...
Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives
Immune-checkpoint inhibitors have become valuable therapies in the treatment of patients with non-small-cell lung cancer (NSCLC). Recent clinical trials have shown promising results with regard to efficacy and toxicity profiles of these agents compared to cytotoxic chemotherapy. Nivolumab was one of...
Guardat en:
| Publicat a: | Onco Targets Ther |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5533488/ https://ncbi.nlm.nih.gov/pubmed/28769573 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S97903 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|